Gideon Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Gideon Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,833	Closed	-$498K	–	460
2018 Q3	$498K	Buy	+10,833	New	+$482K	0.23%	145
2017 Q2	–	Sell	-18,034	Closed	-$346K	–	356
2017 Q1	$346K	Buy	18,034 +2,076	+13%	+$36.8K	0.21%	198
2016 Q4	$267K	Buy	+15,958	New	+$289K	0.17%	301

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gideon Capital Advisors's MYGN Position: Q4 2018 in Review

Gideon Capital Advisors sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 10,833 shares — an estimated $498K sold.

Gideon Capital Advisors first reported a position in MYGN in Q4 2016 and held it in 3 quarters. The position peaked at $498K in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

Gideon Capital Advisors reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
Gideon Capital Advisors sold 10,833 Myriad Genetics shares in Q4 2018, an estimated $498K.
Gideon Capital Advisors first reported a position in Myriad Genetics in Q4 2016 and held it in 3 quarters.
Gideon Capital Advisors's Myriad Genetics position peaked at $498K in Q3 2018.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Gideon Capital Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.